Somatuline^® Autogel^® & Somatuline^® LA 30mg - lanreotide

Description

Somatuline^® Autogel^® Lanreotide (I.N.N.) 60mg, 90mg or 120mg (as acetate), solution for injection in a pre-filled syringe, ready to be injected. White to pale yellow semi-solid formulation as a supersaturated solution.

Active substance

lanreotide

Somatuline^® Autogel^® is indicated for:

• The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalise these values.
• The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.

Somatuline^® LA 30mg is indicated for:

• The treatment of acromegaly when the circulating levels of growth hormone remain abnormal after surgery and/or radiotherapy.
• The treatment of thyrotropic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy.
• The relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours.

GO TO